REGISTER BY CLICKING HERE

THE UNIVERSITY OF SYDNEY

Sydney Cancer Partners
Collaboration, Translation, Impact

9:00 am — **OPENING AND WELCOME**

Session 1.1 Genomics and molecular biology (clinical)
Chair: Gemma Wilson, *The Westmead Institute for Medical Research*

9:20	Dr Braydon Meyer	Identification of DNA methylation biomarkers for prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer	1
9:30	Ms Arjayeeta Samadder	Overcoming Radio-Resistance by Reducing Tumour Oxygen Consumption in Diffuse Intrinsic Pontine Glioma	2
9:40	Dr Geoffrey Yuet Mun Wong	Performance of prognostic models incorporating KRAS mutation status to predict survival after resection of colorectal liver metastases	3
9:50	Ms Tianyi (Eva) Gao	Cyclic and Stapled Peptides for Inhibiting the FANCM-RMI Interaction at Telomeres	4
10:00	Dr Geoffrey Yuet Mun Wong	Recurrence patterns predict survival after resection of colorectal liver metastases	5

10:10 — 10 minute break

Session 1.2 Genomics and molecular biology
Chair: Rachel Teh, *Westmead Institute of Medical Research*

10:20	Dr Pamela Soh	Profiling prostate cancer genetic risk associated with African ancestry	6
10:30	Ms Safaa Al Haj Hussein	Decoding the genome of paediatric cancer patients to identify underlying germline genetic predisposition to cancer development	7
10:40	Ms Xinyu Bai	Identification of novel immunosuppressive mechanisms in adolescent and young adult (AYA) melanoma	8
10:50	Ms Gaya Punnia-Moorthy	The role of KDM6A in melanoma	9
11:00	Ms Gemma Wilson	Integrated Mapping of the Ductal Carcinoma In Situ Ecosystem to Predict Disease Outcome	10
11:10	Ms Zoe Welham	The microbiome in bowel polyps	11

Session 2.1 Quality of Life
Chair: Chloe Lim, *Centre for Medical Psychology and Evidence-Based Decision-Making, School of Psychology*

	Ms Tiffany Li	Assessment of Chemotherapy-Induced Peripheral Neuropathy- A comparison of clinical, functional and patient reported approaches	26
	Dr Carolyn Mazariego-Jones	Priority Recommendations for the Implementation of Patient Reported Outcomes in Clinical Cancer Care: A Delphi study	27
	Dr Vincent Singh Paramanandam	Prophylactic use of compression sleeves reduces the incidence of arm swelling in women at high-risk of breast cancer-related lymphoedema: a randomised controlled trial	28
	Dr Chindhu Shunmuga Sundaram	Prevalence of concerns in Indian Head and Neck Cancer (HNC) populations reported on the Patient concerns Inventory (PCI): A brief report	29
	Ms Madeleine Juhrmann	Palliative Paramedicine: Comparing Clinical Practice through Guideline Quality Appraisal and Qualitative Content Analysis	30

Session 2.2 Psycho-social
Chair: Nicola Fearn, *School of Health Sciences*

	Ms Anna Singleton	Supporting breast cancer survivors via text messages: Reach, acceptability, and utility of EMPOWER-SMS	31
	Ms Kyra Webb	A systematic review and meta-synthesis examining fear of cancer recurrence in informal caregivers	32
	Ms Ashleigh Sharman	Acceptability of an Evidence-Based Booklet for HPV-Related Oropharyngeal Squamous Cell Carcinoma Patients and their Partners	33
	Ms Chloe Lim	Psychosocial and quality of life experiences of people with advanced colorectal cancer: A mixed-methods study	34
	Ms Nicci Bartley	Stakeholder perspectives on the impact of COVID-19 on oncology services: A qualitative study.	35
	Ms Nicci Bartley	Experiences and perspectives of cancer patients/survivors, carers, cancer care healthcare professionals, and non-government cancer services, regarding COVID-19 vaccination	36

11:20 — long break until keynote spekaer (This break covers the PoCoG session times)

1:30 — **KEYNOTE:**
Dr Nicole Rankin, *Convenor of AISN, Director of the Implementation Science (IS) Program at Sydney Health Partners (SHP); Senior Research Fellow, Implementation ScienceSydney School of Public Health*
Implementation Science and Cancer Research: How do we optimise delivery of innovations in practice?
Webinar Registration: https://uni-sydney.zoom.us/webinar/register/WN_U65Raa4US1CTIlA2y4E4Ng

2:15 — **Opening Message and housekeeping announcements** (recorded from Opening session) / additional breaktime for those who joined us earlier

1:25 — 5 minute break

Session 1.3. Cell Biology and Immuno-oncology (part 1)
Chair: Habib Francis, *Centenary Institute of Cancer Medicine and Cell Biology*

2:30	Ms Maha Aman	ECM and its novelty in tumor progression	12
2:40	Mr Mohammad Anisuzzman	Anti-Tumor Activity of Nimotuzumab and Trastuzumab Antibody Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agents Against Skin and Lung Cancers	13
2:50	Mr Daochen Tong	CD123-targeting Chimeric Antigen Receptor T-cells for treating Acute Myeloid Leukemia	14
3:00	Ms Vickie Chan	EGFR trafficking modes involved in cancer resistance to an immunotherapy.	15

Session 2.3. Imaging, Radiology and Surgery
Chair: Andria Yaourtis, *School of Chemistry*

	Mr Sahand Hooshmand	A model to predict the lifetime dose and allocate a dose category from a single screening mammographic event	37
	Mr Zeyad Alawaji	A systematic review reporting the computerised quality control of mammography phantom images	38
	Ms Xuetong Tao	Varying Performance Levels for Diagnosing Mammographic Images Depending on Reader Nationality Have AI and Educational Implications.	39
	Mr James Wood	An octadentate DFOB analogue to improve ligand performance in 89Zr-ImmunoPET imaging.	40

3:10 — 10 minute break

Session 1.4. Cell Biology and Immuno-oncology (continued)
Chair: Miguel Castaneda, *School of Medical Sciences and Charles Perkins Centre*

3:20	Ms Nancy Santiappillai	Fatty Acid Oxidation is a Minor Substrate Source to the TCA Cycle in Prostate Cancer Cells.	16
3:30	Dr Robert Lu	Cell-cycle dependent regulation of non-productive and productive telomere synthesis in cancer cells engaging in Alternative Lengthening of Telomeres	17
3:40	Ms Natasha Freidman	Comfort eating: macropinocytosis as a resistance mechanism in breast cancer following glutamine transporter knockout.	18
3:50	Ms Amy Sarker	PTU, a novel inhibitor of Wnt5a-mediated protrusions, inhibits High Grade Glioma cell invasion in 3-dimensional in vitro models	19

4:00 — 10 minute break

Session 1.5. Novel Treatments
Chair: Josef Gillson, *Bill Walsh Laboratory, Kolling Institute, Northern Clinical School*

4:10	Dr Huaikai Shi	Leptospermum extras suppress malignant pleural mesothelioma tumour growth in vitro and in vivo	20
4:20	Ms Candice Maria Mckertish	Dual payload ADC approach to target and treat HER2+ breast and colon cancer cells.	21
4:30	Mr Reginald Young	Peptide-based inhibitors for targeting telomerase-active cancers	22
4:40	Mrs Farhana Azmi	DEVELOPING RENAL CLEARABLE NANOPARTICLES FOR THE TREATMENT OF RENAL CELL CARCINOMA	23
4:50	Ms Melanie Mach	Off the Shelf Chimeric Antigen Receptor T-cells for Malignancy: A nonviral and site-specific approach	24
5:00	Ms Farhana Mollah	A new strategy to overcome Triple-Negative Breast Cancer metastasis: combining novel targeted therapeutic candidates with an anti-Breast Cancer Associated Fibroblast agent	25

Sesion 2.4. Public Health and Cancer Screening
Chair: Candice Kielly-Carroll, *Charles Perkins Centre*

	Dr Monjura Nisha	Innovative virtual approaches to implementation of clinical trials: a review of current evidence of decentralised clinical trials to summarise design considerations for conducting a "hybrid" clinical trial on melanoma surveillance	41
	Mr Basel Qenam	Test-set training may increase breast screening cancer detection rates	42
	Dr Hankiz Dolan	Australian women's' intentions and psychological outcomes related to breast density notification and information: An online randomised experiment	43
	Ms Jenna Smith	General practitioner's attitudes and behaviours regarding cancer screening in older adults: A qualitative study	44

5:10 — **Closing message**

5:20 — **END**

Prizes sponsored by MERCK